Hollencrest Capital Management trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 64.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,223 shares of the biopharmaceutical company’s stock after selling 5,800 shares during the quarter. Hollencrest Capital Management’s holdings in Gilead Sciences were worth $231,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Welch Investments LLC bought a new position in shares of Gilead Sciences during the third quarter worth $108,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of Gilead Sciences during the third quarter worth $133,000. Horan Capital Advisors LLC. acquired a new stake in shares of Gilead Sciences during the third quarter worth $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Gilead Sciences during the second quarter worth $147,000. Finally, Hanson & Doremus Investment Management raised its holdings in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. 75.71% of the stock is currently owned by institutional investors.
A number of brokerages recently commented on GILD. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price objective on the stock. in a report on Monday, January 29th. Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $88.80 to $76.00 in a report on Tuesday, January 30th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Bank of America raised their price objective on shares of Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday, February 7th. Finally, BMO Capital Markets raised their price objective on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $86.92.
In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 14,435 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total transaction of $1,177,029.90. The disclosure for this sale can be found here. Insiders have sold a total of 432,768 shares of company stock worth $33,919,138 over the last 90 days. 1.30% of the stock is owned by company insiders.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $79.40 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The stock has a market cap of $105,402.85, a price-to-earnings ratio of 9.45, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same period in the previous year, the business earned $2.70 EPS. The company’s revenue was down 18.7% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences, Inc. will post 6.24 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s payout ratio is currently 59.77%.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/23/gilead-sciences-inc-gild-stake-decreased-by-hollencrest-capital-management.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.